Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | IL1B | P01584 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530057 | 1.00 | PDE2A (0.39) | PDE2AIL1BALDH1A1TNFMAPT | |
| SCHEMBL668872 | 0.84 | PDE2A (0.41) | PDE2AALDH1A1MAPTKDM4EPOLB | |
| Fluoride Ion SCHEMBL10713269 | 0.79 | PDE2A (0.38) | PDE2AALDH1A1KDM4EPOLBRECQL | |
| SCHEMBL1531168 | 0.77 | PDE2A (0.37) | PDE2AALDH1A1KDM4EPOLBPLAU | |
| SCHEMBL30754268 | 0.77 | KDM4E (0.39) | PDE2AIL1BALDH1A1TNFMAPT | |
| SCHEMBL22655210 | 0.77 | KDM4E (0.39) | PDE2AIL1BALDH1A1TNFMAPT | |
| SCHEMBL5600053 | 0.77 | ALDH1A1 (0.50) | PDE2AALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL10262533 | 0.76 | PDE2A (0.40) | PDE2AALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL8773859 | 0.74 | PDE2A (0.39) | PDE2AALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL9339616 | 0.74 | PTPN5 (0.41) | PDE2AALDH1A1MAPTKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023160509-A1 | AMIDINE DERIVATIVE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-08-31 | — | — | WO | disclosed |
| CN-116655497-A | Amidine derivative compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-08-29 | — | — | CN | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| CN-105793238-B | Substituted benzamides and methods of use thereof | 基因泰克公司 | 2019-12-24 | — | — | CN | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| EP-2024353-A2 | PYRAZOLE COMPOUNDS | Pfizer Products Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| US-7405240-B2 | Substituted cyclopentanes or cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080119560-A1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080058414-A1 | Substituted Cyclopentanes Or Cyclopentanones As Therapeutic Agents | ALLERGAN, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7323591-B2 | Substituted cyclopentanes or cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| CN-101102989-A | Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertension | ALLERGAN INC (US) | 2008-01-09 | — | — | CN | disclosed |
| US-20070265464-A1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS | OLD DAVID W | 2007-11-15 | — | — | US | disclosed |
| EP-1846354-A2 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES FOR THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | Allergan, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007105058-A2 | PYRAZOLE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006076370-A2 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES FOR THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | ALLERGAN, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119560-A1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS | PDE3A, PTGIR, PTGIS | PDE2A 5/4885IL1B 4737/4885ALDH1A1 1187/4885 |
| US-20080058414-A1 | Substituted Cyclopentanes Or Cyclopentanones As Therapeutic Agents | CYC1, HSPE1, CYP27A1 | PDE2A 97/4885IL1B 3993/4885ALDH1A1 1689/4885 |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | PDE2A 573/4885IL1B 4132/4885ALDH1A1 912/4885 |
| US-20070265464-A1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS | HCCS, MCL1, NME4 | PDE2A 345/4885IL1B 4589/4885ALDH1A1 2087/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | PDE2A 444/4885IL1B 4002/4885ALDH1A1 1306/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | PDE2A 1204/4885IL1B 4242/4885ALDH1A1 1503/4885 |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | PDE2A 573/4885IL1B 4132/4885ALDH1A1 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.